These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24996052)

  • 1. Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review.
    Byers BA; Temple-Oberle CF; Hurdle V; McKinnon JG
    J Surg Oncol; 2014 Nov; 110(6):770-5. PubMed ID: 24996052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-lesional interleukin-2 for the treatment of in-transit melanoma.
    Boyd KU; Wehrli BM; Temple CL
    J Surg Oncol; 2011 Dec; 104(7):711-7. PubMed ID: 21744347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-lesional interleukin-2 therapy for in transit melanoma.
    Temple-Oberle CF; Byers BA; Hurdle V; Fyfe A; McKinnon JG
    J Surg Oncol; 2014 Mar; 109(4):327-31. PubMed ID: 24453036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients.
    Ridolfi L; Ridolfi R; Ascari-Raccagni A; Fabbri M; Casadei S; Gatti A; Trevisan G; Righini MG
    J Eur Acad Dermatol Venereol; 2001 May; 15(3):218-23. PubMed ID: 11683284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
    Radny P; Caroli UM; Bauer J; Paul T; Schlegel C; Eigentler TK; Weide B; Schwarz M; Garbe C
    Br J Cancer; 2003 Nov; 89(9):1620-6. PubMed ID: 14583759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma.
    Khoury S; Knapp GC; Fyfe A; Monzon J; Temple-Oberle C; McKinnon GJ
    J Cutan Med Surg; 2021; 25(4):364-370. PubMed ID: 33529083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2].
    Dehesa LA; Vilar-Alejo J; Valerón-Almazán P; Carretero G
    Actas Dermosifiliogr; 2009 Sep; 100(7):571-85. PubMed ID: 19715642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease.
    Hassan S; Petrella TM; Zhang T; Kamel-Reid S; Nordio F; Baccarelli A; Sade S; Naert K; Habeeb AA; Ghazarian D; Wright FC
    Ann Surg Oncol; 2015; 22(6):1950-8. PubMed ID: 25366584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lesional therapies for in-transit melanoma.
    Nadler A; Look Hong NJ; Alavi N; Abadir W; Wright FC
    J Surg Oncol; 2020 Nov; 122(6):1050-1056. PubMed ID: 32668038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
    Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
    Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locoregional therapies in melanoma.
    Abbott AM; Zager JS
    Surg Clin North Am; 2014 Oct; 94(5):1003-15, viii. PubMed ID: 25245964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
    Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E
    J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma.
    Beasley GM; Zager JS; Thompson JF
    Ann Surg Oncol; 2020 Jan; 27(1):35-42. PubMed ID: 31471842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma].
    Pföhler C; Steinhäuser S; Wagner A; Ugurel S; Tilgen W
    Hautarzt; 2004 Feb; 55(2):171-5. PubMed ID: 14968328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines.
    Patel F; Wilken R; Burrall B; Martinez S; Wells V; King B; Maverakis E
    Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Intra-Lesional Interleukin 2 for the Treatment of In-Transit Melanoma Disease: L'évaluation de l'interleukine-2 intralésionnelle pour traiter les mélanomes en transit.
    Lopez-Obregon B; Barreto MP; Fyfe A; McKinnon G; Webb C; Temple-Oberle C
    Plast Surg (Oakv); 2021 Feb; 29(1):4-9. PubMed ID: 33614534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma.
    Thompson JF; Agarwala SS; Smithers BM; Ross MI; Scoggins CR; Coventry BJ; Neuhaus SJ; Minor DR; Singer JM; Wachter EA
    Ann Surg Oncol; 2015 Jul; 22(7):2135-42. PubMed ID: 25348780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intralesional PV-10 for in-transit melanoma-A single-center experience.
    Lippey J; Bousounis R; Behrenbruch C; McKay B; Spillane J; Henderson MA; Speakman D; Gyorki DE
    J Surg Oncol; 2016 Sep; 114(3):380-4. PubMed ID: 27237868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.
    Green DS; Dalgleish AG; Belonwu N; Fischer MD; Bodman-Smith MD
    Br J Dermatol; 2008 Sep; 159(3):606-14. PubMed ID: 18616776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-transit melanoma: an individualized approach.
    Grotz TE; Mansfield AS; Kottschade LA; Erickson LA; Otley CC; Markovic SN; Jakub JW
    Oncology (Williston Park); 2011 Dec; 25(14):1340-8. PubMed ID: 22329185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.